United Therapeutics Corporation - Asset Resilience Ratio
United Therapeutics Corporation (UTHR) has an Asset Resilience Ratio of 22.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See UTHR current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2024)
This chart shows how United Therapeutics Corporation's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see United Therapeutics Corporation total assets.
Liquid Assets Composition Over Time
This chart breaks down United Therapeutics Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore United Therapeutics Corporation long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.63 Billion | 22.19% |
| Total Liquid Assets | $1.63 Billion | 22.19% |
Asset Resilience Insights
- Good Liquidity Position: United Therapeutics Corporation maintains a healthy 22.19% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
United Therapeutics Corporation Industry Peers by Asset Resilience Ratio
Compare United Therapeutics Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for United Therapeutics Corporation (1999–2024)
The table below shows the annual Asset Resilience Ratio data for United Therapeutics Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 21.32% | $1.57 Billion | $7.36 Billion | -3.61pp |
| 2023-12-31 | 24.93% | $1.79 Billion | $7.17 Billion | -6.14pp |
| 2022-12-31 | 31.06% | $1.88 Billion | $6.04 Billion | +11.02pp |
| 2021-12-31 | 20.04% | $1.04 Billion | $5.17 Billion | -3.71pp |
| 2020-12-31 | 23.76% | $1.10 Billion | $4.62 Billion | +4.65pp |
| 2019-12-31 | 19.10% | $747.50 Million | $3.91 Billion | -2.85pp |
| 2018-12-31 | 21.96% | $746.70 Million | $3.40 Billion | +14.23pp |
| 2017-12-31 | 7.72% | $222.30 Million | $2.88 Billion | +6.52pp |
| 2016-12-31 | 1.20% | $27.80 Million | $2.33 Billion | -4.39pp |
| 2015-12-31 | 5.58% | $122.00 Million | $2.18 Billion | -10.22pp |
| 2014-12-31 | 15.81% | $297.84 Million | $1.88 Billion | -3.82pp |
| 2013-12-31 | 19.62% | $409.64 Million | $2.09 Billion | -0.37pp |
| 2012-12-31 | 19.99% | $325.18 Million | $1.63 Billion | +4.13pp |
| 2011-12-31 | 15.86% | $240.80 Million | $1.52 Billion | -10.33pp |
| 2010-12-31 | 26.19% | $374.92 Million | $1.43 Billion | +13.91pp |
| 2009-12-31 | 12.28% | $129.14 Million | $1.05 Billion | +0.05pp |
| 2008-12-31 | 12.23% | $106.60 Million | $871.32 Million | -13.44pp |
| 2007-12-31 | 25.68% | $150.73 Million | $587.02 Million | -2.88pp |
| 2006-12-31 | 28.56% | $136.68 Million | $478.55 Million | +9.24pp |
| 2005-12-31 | 19.32% | $56.30 Million | $291.41 Million | +19.22pp |
| 2004-12-31 | 0.10% | $200.00K | $207.16 Million | -17.07pp |
| 2002-12-31 | 17.16% | $31.68 Million | $184.57 Million | +2.23pp |
| 2001-12-31 | 14.93% | $31.68 Million | $212.12 Million | +9.15pp |
| 2000-12-31 | 5.78% | $14.48 Million | $250.64 Million | -49.81pp |
| 1999-12-31 | 55.59% | $33.30 Million | $59.90 Million | -- |
About United Therapeutics Corporation
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer;… Read more